188 related articles for article (PubMed ID: 28132538)
1. [The safety of anti-diabetic drugs in heart failure].
Frigy A; Germán-Salló M; Máthé L; Szabó M
Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538
[TBL] [Abstract][Full Text] [Related]
2. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
Sisson EM; Mills J; Chin L
Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
[No Abstract] [Full Text] [Related]
3. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
4. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Kappel BA; Marx N; Federici M
Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
[TBL] [Abstract][Full Text] [Related]
5. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
6. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Valerón PF; de Pablos-Velasco PL
Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
[TBL] [Abstract][Full Text] [Related]
7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
[No Abstract] [Full Text] [Related]
10. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
11. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
12. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Barnett AH
Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
[TBL] [Abstract][Full Text] [Related]
13. Can genetics improve precision of therapy in diabetes?
Groop L; Storm P; Rosengren A
Trends Endocrinol Metab; 2014 Sep; 25(9):440-3. PubMed ID: 25028244
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
[TBL] [Abstract][Full Text] [Related]
15. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones.
Wong AK; Struthers AD; Choy AM; Lang CC
Heart Fail Clin; 2012 Oct; 8(4):539-50. PubMed ID: 22999238
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
17. Clinical decisions. Management of type 2 diabetes.
Goldberg RB; Holman R; Drucker DJ
N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
[No Abstract] [Full Text] [Related]
18. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Strowig SM; Raskin P
Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
